The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

Sydney, Australia, 28 November 2024 – Celosia Therapeutics, an Australian biotech company developing advanced gene therapies ...

Philadelphia dad Eric Brunner was diagnosed with amyotrophic lateral sclerosis, the fatal disease known as ALS. He wants to ...

In a new study of mouse cells, scientists found that both the biochemical and mechanical effects of exercise may help injured ...

A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...

A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...